The roll-up thesis: durable growth, margin expansion, recurring-revenue quality, prudent leverage and disciplined capital allocation.
The roll-up thesis is proving out: 3 integrated cohorts delivered +281pts of EBITDA margin and leverage sits at 0.7x against the 5.5x covenant. The remaining value is in the 4 unintegrated cohorts — finish synergy capture before exit diligence prices it.
5 of 6 headline metrics improving vs prior · still off target: Revenue $44.05B vs $46.00B, EBITDA Margin 23.3% vs 24.0%, Rule of 40 44 vs 45
Sets deal capacity and refinancing risk.
4 of 7 cohorts sit below 80% synergy capture; integrated cohorts already show +281pts of margin — the same playbook is unbanked EBITDA until applied.
Hold management to 90-day synergy recovery plan; track at next board meeting.
Synergy at 78% of model; integration 80% complete.
Push subscription/Skin Genius AI-powered skin analysis attach on Integration installs.
Recurring 40% vs 45% strategic target; Integration BU dilutive.
Consistent top-line growth with steady margin expansion.
Proof of the roll-up: EBITDA uplift and synergy realization per acquired brand.
| Acquired brand | Year | Revenue | ARR | EBITDA uplift | Synergy | Status |
|---|---|---|---|---|---|---|
| Lancôme | 2021 | $1907.9M | $673.38M | 505.03%→785.61% (+280.58000000000004) | 92% | Integrated |
| Garnier | 2021 | $1234.52M | $448.92M | 448.92%→729.49% (+280.57) | 90% | Integrated |
| L'Oréal Paris | 2022 | $5387.01M | $2917.96M | 617.26%→897.83% (+280.57000000000005) | 88% | Integrated |
| La Roche-Posay | 2023 | $3254.65M | $1066.18M | 561.15%→729.49% (+168.34000000000003) | 74% | In progress |
| Kérastase | 2024 | $2300.7M | $785.61M | 505.03%→617.26% (+112.23000000000002) | 55% | In progress |
| Maybelline New York | 2024 | $2076.24M | $729.49M | 505.03%→673.38% (+168.35000000000002) | 78% | In progress |
| Vichy | 2024 | $1627.32M | $505.03M | 448.92%→505.03% (+56.10999999999996) | 40% | Early |
Integrated cohorts (AFA, Firecom, DavEd) show ~281pt EBITDA expansion post-integration; newer cohorts (ISC, Signet) remain early with synergy capture in progress.
Covenant headroom funds the continued M&A program; cash generation supports debt service.
High-materiality external signals and competitive M&A from the adapter feed.